In the last trading session, 1.12 million shares of the Viridian Therapeutics Inc (NASDAQ:VRDN) were traded, and its beta was 0.66. Most recently the company’s share price was $13.30, and it changed around $1.28 or 10.65% from the last close, which brings the market valuation of the company to $1.08B. VRDN currently trades at a discount to its 52-week high of $27.20, offering almost -104.51% off that amount. The share price’s 52-week low was $9.90, which indicates that the current value has risen by an impressive 25.56% since then. We note from Viridian Therapeutics Inc’s average daily trading volume that its 10-day average is 1.26 million shares, with the 3-month average coming to 978.18K.
Viridian Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.24. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 2 recommended VRDN as a Hold, whereas 10 deemed it a Buy, and 0 rated it as Underweight. Viridian Therapeutics Inc is expected to report earnings per share of -0.96 for the current quarter.
Viridian Therapeutics Inc (NASDAQ:VRDN) trade information
Instantly VRDN has showed a green trend with a performance of 10.65% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 13.46 on recent trading dayincreased the stock’s daily price by 1.19%. The company’s shares are currently down -30.62% year-to-date, but still up 12.90% over the last five days. On the other hand, Viridian Therapeutics Inc (NASDAQ:VRDN) is -16.46% down in the 30-day period. We can see from the shorts that 10.16 million shares have been sold at a short interest cover period of 12.4 day(s).
The consensus price target as assigned by Wall Street analysts is $20.5, which translates to bulls needing to increase their stock price by 35.12% from its current value. Analyst projections state that VRDN is forecast to be at a low of $20.5 and a high of $20.5.
Viridian Therapeutics Inc (VRDN) estimates and forecasts
The year-over-year growth rate is expected to be -46.92%, down from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 44.08k in revenue for the current quarter. 13 analysts expect Viridian Therapeutics Inc to make 44.08k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 72k and 72k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -38.78%. Forecasts for the next quarter put sales growth at -38.78%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 31.28%. Viridian Therapeutics Inc earnings are expected to increase by -6.05% in 2025, but the outlook is positive 23.74% per year for the next five years.
VRDN Dividends
Viridian Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Viridian Therapeutics Inc (NASDAQ:VRDN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.12% of Viridian Therapeutics Inc shares, and 113.87% of them are in the hands of institutional investors. The stock currently has a share float of 114.01%. Viridian Therapeutics Inc stock is held by 251.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 14.9924% of the shares, which is about 9.57 million shares worth $124.55 million.
BLACKROCK INC., with 7.4758% or 4.77 million shares worth $62.1 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Select Portfolios-Health Care Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Feb 28, 2025 . The former held 2.3 shares worth $30.53 million, making up 2.82% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 2.22 shares worth around $29.52 million, which represents about 2.72% of the total shares outstanding.
